Cargando…

Retinal Hemorrhage after SARS-CoV-2 Vaccination

To report retinal vein occlusion (RVO) and age-related macular degeneration (AMD)-related submacular hemorrhage developing after administration of SARS-CoV-2 vaccines, a single-center, retrospective observational case series was conducted. Clinical data including fundus photographs and optical coher...

Descripción completa

Detalles Bibliográficos
Autores principales: Park, Hyo Song, Byun, Yeojue, Byeon, Suk Ho, Kim, Sung Soo, Kim, Yong Joon, Lee, Christopher Seungkyu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8658415/
https://www.ncbi.nlm.nih.gov/pubmed/34884407
http://dx.doi.org/10.3390/jcm10235705
_version_ 1784612727233183744
author Park, Hyo Song
Byun, Yeojue
Byeon, Suk Ho
Kim, Sung Soo
Kim, Yong Joon
Lee, Christopher Seungkyu
author_facet Park, Hyo Song
Byun, Yeojue
Byeon, Suk Ho
Kim, Sung Soo
Kim, Yong Joon
Lee, Christopher Seungkyu
author_sort Park, Hyo Song
collection PubMed
description To report retinal vein occlusion (RVO) and age-related macular degeneration (AMD)-related submacular hemorrhage developing after administration of SARS-CoV-2 vaccines, a single-center, retrospective observational case series was conducted. Clinical data including fundus photographs and optical coherence tomography (OCT) scans were reviewed. Twenty-three eyes of 21 patients were included with the median age at symptom presentation being 77 years (range: 51–85 years). Twelve eyes (52.2%) had submacular hemorrhage and 11 (47.8%) had RVO. Twelve patients (60.9%) had been vaccinated with the Pfizer vaccine (BNT162b2) and 8 with the AstraZeneca (ChAdOx1) vaccine. Sixteen patients (76.2%) experienced ocular disease exacerbation after the first vaccination and 4 (19.0%) after the second vaccination. The median visual acuity (logarithm of the minimal angle of resolution; logMAR) before symptom development was 0.76 (interquartile range: 0.27–1.23); the median logMAR at symptom presentation was 1.40 (interquartile range 0.52–1.70). The median time between vaccination and symptom exacerbation was 2.0 days (interquartile range: 1.0–3.0 days). Five patients (23.8%) underwent tests for hematological abnormalities, including the presence of anti-PF4 antibodies; all were negative. Further studies with larger patient group for evaluation of effect of SARS-CoV-2 vaccination on retinal hemorrhage are necessary.
format Online
Article
Text
id pubmed-8658415
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-86584152021-12-10 Retinal Hemorrhage after SARS-CoV-2 Vaccination Park, Hyo Song Byun, Yeojue Byeon, Suk Ho Kim, Sung Soo Kim, Yong Joon Lee, Christopher Seungkyu J Clin Med Article To report retinal vein occlusion (RVO) and age-related macular degeneration (AMD)-related submacular hemorrhage developing after administration of SARS-CoV-2 vaccines, a single-center, retrospective observational case series was conducted. Clinical data including fundus photographs and optical coherence tomography (OCT) scans were reviewed. Twenty-three eyes of 21 patients were included with the median age at symptom presentation being 77 years (range: 51–85 years). Twelve eyes (52.2%) had submacular hemorrhage and 11 (47.8%) had RVO. Twelve patients (60.9%) had been vaccinated with the Pfizer vaccine (BNT162b2) and 8 with the AstraZeneca (ChAdOx1) vaccine. Sixteen patients (76.2%) experienced ocular disease exacerbation after the first vaccination and 4 (19.0%) after the second vaccination. The median visual acuity (logarithm of the minimal angle of resolution; logMAR) before symptom development was 0.76 (interquartile range: 0.27–1.23); the median logMAR at symptom presentation was 1.40 (interquartile range 0.52–1.70). The median time between vaccination and symptom exacerbation was 2.0 days (interquartile range: 1.0–3.0 days). Five patients (23.8%) underwent tests for hematological abnormalities, including the presence of anti-PF4 antibodies; all were negative. Further studies with larger patient group for evaluation of effect of SARS-CoV-2 vaccination on retinal hemorrhage are necessary. MDPI 2021-12-05 /pmc/articles/PMC8658415/ /pubmed/34884407 http://dx.doi.org/10.3390/jcm10235705 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Park, Hyo Song
Byun, Yeojue
Byeon, Suk Ho
Kim, Sung Soo
Kim, Yong Joon
Lee, Christopher Seungkyu
Retinal Hemorrhage after SARS-CoV-2 Vaccination
title Retinal Hemorrhage after SARS-CoV-2 Vaccination
title_full Retinal Hemorrhage after SARS-CoV-2 Vaccination
title_fullStr Retinal Hemorrhage after SARS-CoV-2 Vaccination
title_full_unstemmed Retinal Hemorrhage after SARS-CoV-2 Vaccination
title_short Retinal Hemorrhage after SARS-CoV-2 Vaccination
title_sort retinal hemorrhage after sars-cov-2 vaccination
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8658415/
https://www.ncbi.nlm.nih.gov/pubmed/34884407
http://dx.doi.org/10.3390/jcm10235705
work_keys_str_mv AT parkhyosong retinalhemorrhageaftersarscov2vaccination
AT byunyeojue retinalhemorrhageaftersarscov2vaccination
AT byeonsukho retinalhemorrhageaftersarscov2vaccination
AT kimsungsoo retinalhemorrhageaftersarscov2vaccination
AT kimyongjoon retinalhemorrhageaftersarscov2vaccination
AT leechristopherseungkyu retinalhemorrhageaftersarscov2vaccination